Document:

cbmg_ex101

 

 Exhibit 10.1

 

Cellular
Biomedicine (Wuxi) Co., Ltd. - Basic Line of Credit -
2020042800000284

 

	

Stage:
Business application investigation

 

	

Handler:
Qian Zheng

 

	

Organization
of the handler: Renmin Zhonglu Sub-branch, Wuxi Branch

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate: Floating rate

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/28/2020, 18:08:33

 

	

Completed
at: 4/28/2020, 18:53:05

 

	

[Opinion] It is proposed to grant the basic line of credit of RMB
30 million to Cellular Biomedicine (Wuxi) Co., Ltd. for the purpose
of covering the company’s operation, maintenance and R&D
expenditures. The term of the line of credit is one year and the
loan is a working capital loan with the characteristics of interest
rate of not lower than LPR +50BP, monthly settlement, fixed
interest rate, custodian payment, and the guarantee method of
credit. Please approve.

	

[Opinion (cont.)]

 

 

 

 

	

Stage:
Branch risk manager

 

	

Handler:
Li Bo

 

	

Organization
of the handler: Wuxi Branch

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:

 

	

Business
currency:

 

	

Amount
under application (RMB): 0.00

 

	

Term
(months): 0

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/28/2020, 18:53:05

 

	

Completed
at: 4/29/2020, 10:02:36

 

	

[Opinion] The following risk control measures are recommended: 1.
Pay attention to changes in the country's macro policies and pay
close attention to the price changes of major raw materials. 2.
Strengthen credit management and pay attention to the company's
management and control in production, market, capital and other
aspects. 3. Effectively strengthen post-loan management and conduct
credit risk analysis in a timely manner to ensure the safety of the
bank's credit funds.

	

[Opinion (cont.)]

 

 

 

  

	

Stage:
Head of the Marketing Department

 

	

Handler:
Ruan Haotian

 

	

Organization
of the handler: Wuxi Branch

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/29/2020, 10:02:36

 

	

Completed
at: 4/29/2020, 15:10:40

 

	

[Opinion] Agree

	

[Opinion (cont.)]

 

 

 

 

	

Stage:
Branch analysis and evaluation (beyond the branch’s
authority)

 

	

Handler:
Xu Daoyou

 

	

Organization
of the handler: Wuxi Branch

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/29/2020, 15:21:17

 

	

Completed
at: 4/29/2020, 17:11:58

 

	

[Opinion] It is proposed to grant the basic line of credit of RMB
30 million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.

	

[Opinion (cont.)]

 

 

 

 

	

Stage:
Branch Risk Director (beyond the branch’s
authority)

 

	

Handler:
Huang Yonghong

 

	

Organization
of the handler: Wuxi Branch

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/29/2020, 17:11:58

 

	

Completed
at: 4/29/2020, 17:25:30

 

	

[Opinion] We agree to declare this.

	

[Opinion (cont.)]

 

 

 

 

	

Stage:
Branch governor (beyond the branch’s authority)

 

	

Handler:
Zhou Bo

 

	

Organization
of the handler: Wuxi Branch

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/29/2020, 17:25:30

 

	

Completed
at: 4/29/2020, 17:40:06

 

	

[Opinion] Agree

	

[Opinion (cont.)]

 

 

 

 

	

Stage:
Pre-examination at the headquarters

 

	

Handler:
Dai Jun

 

	

Organization
of the handler: Bank of Nanjing

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:
Fully authorized

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

 

 

 

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/30/2020, 8:40:31

 

	

Completed
at: 4/30/2020, 10:20:41

 

	

[Opinion] We agree to grant the basic line of credit of RMB 30
million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.Operations carried out with the line of credit
should be reported to the headquarters for approval.

	

[Opinion (cont.)]

 

 

 

 

	

Stage:
Countersigning stage at the headquarters

 

	

Handler:
Zhu Hua

 

	

Organization
of the handler: Bank of Nanjing

 

	

Customer
name: Cellular Biomedicine (Wuxi) Co., Ltd.

 

	

Business
type: Basic line of credit

 

	

Authorization:
Not authorized

 

	

Business
currency: RMB

 

	

Amount
under application (RMB): 30,000,000.00

 

	

Term
(months): 12

 

	

Day(s):
0

 

	

Interest
rate type:

 

	
 

	

Base
annual interest rate (%): 0.0

 

	

Floating
interest rate:

 

	

Floating
value: 0.0

 

	

Annual
interest rate (%): 0.0

 

	

Handling
fee rate (‰): 0.00

 

	

Margin
ratio (%): 0

 

	

Received
at: 4/30/2020, 10:55:19

 

	

Completed
at: 4/30/2020, 16:06:50

 

	

[Opinion] We agree to grant the basic line of credit of RMB 30
million to Cellular Biomedicine (Wuxi) Co., Ltd. The term of the
line of credit is one year and the loan is a working capital loan
with the characteristics of interest rate of not lower than LPR
+50BP. This loan is to be used to pay the company’s
operation, maintenance and R&D expenditures.Credit conditions
and management requirements:1. If the bank's loan is already
issued, attention should be paid to the privatization process of
the group's parent company. The bank's loan should be repaid in
time once new investment capital is injected into the company.2. To
monitor the use of the loan, our bank’s loan is only used for
the daily operation, maintenance and R&D expenditures of the
company.3. Attention should be paid to the progress of the
borrower’s clinical trials, funds and operations. If there
are any adverse conditions that affect the safety of our
bank’s credit funds, the credit strategy should be adjusted
in a timely manner.Operations carried out with the line of credit
should be reported to the headquarters for approval.

	

[Opinion (cont.)]EX-10.1

 Exhibit 10.1 
  

					
	DocuSign Envelope ID: 
E25578FB-4593-FFC1-9237-059352B386FA	 	

	 	

 U.S. Small Business Administration 

PAYCHECK PROTECTION PROGRAM LOAN NOTE 
  

			
	SBA Loan#	  	PLP# 37765472-00
		
	SBA Loan Name	  	INHIBITOR THERAPEUTICS, INC.
		
	Date	  	05/02/2020
		
	Loan Amount	  	$41,600.00
		
	Interest Rate	  	1.00%
		
	Borrower	  	INHIBITOR THERAPEUTICS, INC.
		
	Lender	  	Citibank, N.A.
		
	Maturity Date	  	5/2/2022

  

	1.	 PROMISE TO PAY: 

In return for the Loan, Borrower promises to pay to the order of Lender the Loan Amount specified above, interest on the unpaid principal
balance, and all other amounts required by this Note as specified below. 
  

	2.	 DEFINITIONS: 

“Loan” means the loan evidenced by this Note. 

“Loan Documents” means the documents related to the Loan signed and delivered by Borrower. 

“SBA” means the Small Business Administration, an Agency of the United States of America. 

 

	3.	 PAYMENT TERMS: 

Borrower must make all payments at the place Lender designates. The payment terms for this Note are: 

The interest rate is fixed as specified above and will not change during the life of the Loan. 

No payments are due on the Loan for six (6) months (the “Deferment Period”) from the date of first
disbursement of the Loan. Interest will continue to accrue during the Deferment Period. Borrower must make principal and interest payments every month beginning in the month immediately following the end of the Deferment Period (the “Payment
Commencement Date”) in an amount calculated at the interest rate specified herein and based on the amount of the unpaid principal balance hereunder as of the Payment Commencement Date and a final payment on the Maturity Date equal to all unpaid
interest, principal, and fees. Payments must be made on the same calendar day of each month as the date of this Note in the months they are due. Borrower shall also pay on the Payment Commencement Date all accrued interest on the unpaid
principal balance of this Note from the date of first disbursement of the Loan through the Payment Commencement Date. 

  

					
	PPP Loan Note CCB 4-7-20 V .2.0	  	Page1/5	  	

					
	DocuSign Envelope ID: 
E25578FB-4593-FFC1-9237-059352B386FA	 	

	 	

 U.S. Small Business Administration 

PAYCHECK PROTECTION PROGRAM LOAN NOTE 
  

 Lender will apply each installment payment first to pay interest accrued on the Loan to the
day Lender receives the payment, then to bring principal current, then to pay any late fees, and then to any remaining balance to reduce the outstanding principal balance of this Note. 

NOTICE - LOAN FORGIVENESS: Borrower may apply through Lender for forgiveness of the amount due on this Loan in an amount equal to the sum
of the following costs incurred by Borrower during the 8-week period (or any other period that may hereafter be authorized by SBA) beginning on the date of first disbursement of the Loan: 

a. Payroll costs 

b. Any payment of interest on a covered mortgage obligation (which shall not include any prepayment of or payment of
principal on a covered mortgage obligation) 
 c. Any payment on a covered rent obligation 

d. Any covered utility payment 

The amount of Loan forgiveness shall be calculated (and may be reduced) in accordance with the requirements of the Paycheck Protection
Program, including the provisions of Section 1106 of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) (P.L. 116-136). Borrower covenants and agrees to use the Loan only for purposes
authorized by the CARES Act. Not more than twentyfive (25%) percent of the amount forgiven can be attributable to non-payroll costs. The amount of each monthly Loan payment due hereunder will change to the
extent SBA determines that Borrower has met the eligibility requirements under the CARES Act and pays to Lender the amount of the Loan that is entitled to forgiveness. If the entire principal amount of the Loan is forgiven and the Note indebtedness
is paid to Lender by the SBA, no further principal payments under this Note shall be payable by Borrower. 
  

	4.	 LOAN PREPAYMENT/LATE CHARGE: 

Notwithstanding any provision of this Note to the contrary, Borrower may prepay all or any part of the unpaid principal balance of this Note
without premium or penalty at any time without notice. Borrower may prepay twenty (20%) percent or less of the unpaid principal balance at any time without notice. If Borrower prepays more than twenty (20%) percent and the Loan has been sold on the
secondary market, Borrower must (a) give Lender written notice; (b) pay all accrued interest; and (c) if the prepayment is received less than twenty-one (21) days from the date Lender
received the notice, pay an amount equal to twenty-one (21) days interest from the date Lender received the notice, less any interest accrued during the twenty-one
(21) days and paid under (b) of this paragraph. If Borrower does not prepay within thirty (30) days from the date Lender received the notice, Borrower must give Lender a new notice. 

All unpaid principal and accrued interest is due and payable two years from the date of this Note. 

Late Charge: If a payment on this Note is more than 15 days late, Lender may charge Borrower a late fee of up to 4.00% of
the unpaid portion of the regularly scheduled payment. 
  

	5.	 REPRESENTATIONS AND WARRANTIES: 

Borrower represents and warrants to Lender as of the date of this Note that: 

 

	 	A.	 Borrower is duly organized, validly existing, and in good standing under and by virtue of the laws of the state
in which it has been formed. 

  

					
	PPP Loan Note CCB 4-7-20 V .2.0	  	Page2/5	  	

					
	DocuSign Envelope ID: 
E25578FB-4593-FFC1-9237-059352B386FA	 	

	 	

 U.S. Small Business Administration 

PAYCHECK PROTECTION PROGRAM LOAN NOTE 
  

	 	B.	 Borrower is duly authorized to transact business in all other states in which Borrower is doing business,
having obtained all necessary filings, governmental licenses and approvals for each state in which Borrower is doing business; Borrower’s execution, delivery, and performance of this Note and any Loan Documents have been duly authorized by all
necessary action by Borrower and do not conflict with, result in a violation of, or constitute a default under (1) any provision of (a) Borrower’s articles of incorporation or organization, or bylaws, or (b) any agreement or
other instrument binding upon Borrower, or (2) any law, governmental regulation, court decree, or order applicable to Borrower or to Borrower’s properties. 

 

	 	C.	 This Note has been duly executed and delivered by the undersigned as a duly authorized representative of
Borrower, and is Borrower’s legal, valid and binding obligation enforceable against Borrower in accordance with its terms. 

  

	 	D.	 All financial, tax, payroll costs, and other information submitted to Lender, including in connection with
Borrower’s application for the loan evidenced by this Note is true, correct, and complete as of the date of this Note. 

  

	6.	 DEFAULT: 

Borrower will be in default under this Note if Borrower does not make a payment when due under this Note, or if Borrower: 

 

	 	A.	 Fails to do anything required by this Note or in any document executed or delivered in connection with this
Note; 

  

	 	B.	 Defaults on any other loan with Lender; 

 

	 	C.	 Does not disclose, or anyone acting on their behalf does not disclose, any material fact to Lender or SBA;

  

	 	D.	 Makes, or anyone acting on their behalf makes, a materially false or misleading representation, information
submission, or certification to Lender or SBA, including in respect of any representation or warranty contained in this Note; 

  

	 	E.	 Defaults on any loan or agreement with another creditor, if Lender believes the default may materially affect
Borrower’s ability to pay this Note; 

  

	 	F.	 Fails to pay any taxes when due; 

 

	 	G.	 Becomes the subject of a proceeding under any bankruptcy or insolvency law; 

 

	 	H.	 Has a receiver or liquidator appointed for any part of their business or property; 

 

	 	I.	 Makes an assignment for the benefit of creditors; 

 

	 	J.	 Has any adverse change in financial condition or business operation that Lender believes may materially affect
Borrower’s ability to pay this Note; 

  

	 	K.	 Reorganizes, merges, consolidates, or otherwise changes ownership or business structure without Lender’s
prior written consent; or 

  

	 	L.	 Becomes the subject of a civil or criminal action that Lender believes may materially affect Borrower’s
ability to pay this Note. 

  

	7.	 LENDER’S RIGHTS IF THERE IS A DEFAULT: 

Without notice or demand and without giving up any of its rights, Lender may: 

 

	 	A.	 Require immediate payment of all amounts owing under this Note; 

 

	 	B.	 Collect all amounts owing from any Borrower; or 

 

	 	C.	 File suit and obtain judgment. 

  

					
	PPP Loan Note CCB 4-7-20 V .2.0	  	Page3/5	  	

					
	DocuSign Envelope ID: 
E25578FB-4593-FFC1-9237-059352B386FA	 	

	 	

 U.S. Small Business Administration 

PAYCHECK PROTECTION PROGRAM LOAN NOTE 
  

	8.	 LENDER’S GENERAL POWERS: 

Without notice and without Borrower’s consent, Lender may: 
  

	 	A.	 Incur expenses to collect amounts due under this Note, enforce the terms of this Note or any other Loan
Document. Among other things, the expenses may include payments for prior liens and reasonable attorney’s fees and costs. If Lender incurs such expenses, it may demand immediate repayment from Borrower or add the expenses to the principal
balance of this Note; 

  

	 	B.	 Release anyone obligated to pay this Note; and 

 

	 	C.	 Take any action necessary to collect amounts owing on this Note. 

 

	9.	 WHEN FEDERAL LAW APPLIES: 

When SBA is the holder, this Note will be interpreted and enforced under federal law, including SBA regulations. As to this Note, Borrower may
not claim or assert against SBA any local or state law to deny any obligation, defeat any claim of SBA, or preempt federal law. 
  

	10.	 NON-RECOURSE: 

Lender and SBA shall have no recourse against any individual shareholder, member or partner of Borrower for non-payment of the Loan, except to
the extent that such shareholder, member or partner uses the Loan proceeds for an unauthorized purpose. 
  

	11.	 SUCCESSORS AND ASSIGNS: 

Under this Note, Borrower includes any of its successors, and Lender includes its successors and assigns. 

 

	12.	 GENERAL PROVISIONS: 

 

	 	A.	 All individuals and entities signing this Note are jointly and severally liable. 

 

	 	B.	 Borrower waives all suretyship defenses. 

 

	 	C.	 Borrower must sign all documents necessary at any time to comply with the Loan Documents.

  

	 	D.	 Lender may exercise any of its rights separately or together, as many times and in any order it chooses. Lender
may delay or forgo enforcing any of its rights without giving up any of them. 

  

	 	E.	 Borrower may not use an oral statement of Lender or SBA to contradict or alter the written terms of this Note.

  

	 	F.	 If any part of this Note is unenforceable, all other parts remain in effect. 

 

	 	G.	 To the extent allowed by law, Borrower waives all demands and notices in connection with this Note, including
presentment, demand, protest, and notice of dishonor. 

  

	 	H.	 Borrower shall use all Loan proceeds solely for Borrower’s business operations and strictly in accordance
with the requirements of the CARES Act. 

  

	 	I.	 Until such time as all of Borrower’s Loans have been either forgiven or paid in full and this Note has
been cancelled, Borrower agrees to maintain its Primary Demand Deposit Account with Lender. “Primary Demand Deposit Account” means the business demand deposit account into which substantially all of Borrower’s receipts from its
operations are deposited and from which substantially all of Borrower’s disbursements for its operations are made. 

  

	 	J.	 Except as otherwise provided in Section 9 hereof, this Note shall be governed by and construed in
accordance with the laws of the State of New York, without regard to its conflicts of law provisions. 

  

	 	K.	 If there is a lawsuit, Borrower agrees, upon Lender’s request, to submit to the jurisdiction of the courts
of New York County, State of New York. Nothing herein shall affect the right of the Lender to bring any action or proceeding against the Borrower in the courts of any other jurisdiction. 

  

					
	PPP Loan Note CCB 4-7-20 V .2.0	  	Page4/5	  	

					
	DocuSign Envelope ID: 
E25578FB-4593-FFC1-9237-059352B386FA	 	

	 	

 U.S. Small Business Administration 

PAYCHECK PROTECTION PROGRAM LOAN NOTE 
  

	 	L.	 BORROWER HEREBY WAIVES THE RIGHT TO A TRIAL BY JURY IN ANY ACTION, PROCEEDING, OR COUNTERCLAIM ARISING UNDER
OR IN CONNECTION WITH THIS NOTE OR ANY LOAN DOCUMENT TO THE EXTENT PERMITTED BY APPLICABLE LAW. 

  

	 	M.	 Delivery of an executed counterpart of a signature page of this Note by telecopy or other digital or electronic
imaging means shall be effective as delivery of a manually executed counterpart of this Note. 

  

	13.	 BORROWER’S NAME(S) AND SIGNATURE(S): 

By signing below, each entity becomes obligated under this Note as Borrower. 

FOR LEGAL ENTITIES: 

					
			
		 	Name of Borrower:	 	INHIBITOR THERAPEUTICS, INC.

					
			
		 	By:	 	

					
			
		 	Name:	 	Garry Hasara

					
			
		 	Title:	 	Chief Financial Officer

  

					
	PPP Loan Note CCB 4-7-20 V .2.0	  	Page5/5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]